Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
356 stopped studies mapped to Malignant Glioma and descendants · 90% state a reason
Over the 356 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT02654041 | Study of Induction of Hypothyroxinemia Adjunct to Conventional Therapies in GBM Patients | Phase 2 | terminated | Jan 13, 2016 | Musli Thyropeutics Ltd. | Drug manufacturer no longer could supply for study | Drug supply |
| NCT02254954 | Clinical Study on Macitentan, RT and TMZ Concurrent Therapy Followed by Maintenance… | Phase 1 | terminated | Oct 2, 2014 | Actelion | Sponsor decision due to low recruitment | Enrollment / accrual |
| NCT01788280 | Preliminary Assessment of [18F] Fluciclatide (GE [18F]AH111585) in Glioblastoma… | Phase 2 | withdrawn | Feb 11, 2013 | University of Utah | Unable to get materials from GE, study not proceeding and never opened to accrual | Enrollment / accrual |
| NCT02047214 | Safety & Efficacy Study of TPI 287 + Avastin in Adults With Glioblastoma That Progressed… | Phase 2 | terminated | Jan 28, 2014 | Cortice Biosciences, Inc. | Due to lack of clinical benefit in the 17 subjects enrolled in the trial to date | Efficacy / futility |
| NCT02590497 | Correlation Between the Genetic and Neuroimaging Signatures in Newly Diagnosed… | N/A | withdrawn | Oct 29, 2015 | Ohio State University Comprehensive Cancer Center | PI made decision | Other (stated, no rule matched) |
| NCT01782976 | Ph II Cilengitide Plus Bevacizumab for Recurrent Glioblastoma (GBM) | Phase 2 | withdrawn | Feb 4, 2013 | M.D. Anderson Cancer Center | not stated | Not stated |
| NCT02348255 | NovoTTF-100A With Bevacizumab and Carmustine in Treating Patients With Glioblastoma… | Phase 2 | withdrawn | Jan 28, 2015 | University of California, Davis | Poor Accrual | Enrollment / accrual |
| NCT01339039 | Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma | Phase 1 | terminated | Apr 20, 2011 | Patrick Y. Wen, MD | Low accrual rate | Enrollment / accrual |
| NCT02510950 | Neoepitope-based Personalized Vaccine Approach in Patients With Newly Diagnosed… | Phase 1 | terminated | Jul 29, 2015 | Washington University School of Medicine | Low accrual | Enrollment / accrual |
| NCT01666600 | NOA-12: BIBF1120 and R-RT in Glioblastoma | Phase 1 / Phase 2 | terminated | Aug 16, 2012 | Prof. Dr. Wolfgang Wick | Interim Analysis for Feasibility | Efficacy / futility |
| NCT02329795 | Image-derived Prediction of Response to Chemo-radiation in Glioblastoma(IDEPREG) | — | terminated | Jan 1, 2015 | Rigshospitalet, Denmark | Slow accrual | Enrollment / accrual |
| NCT01508117 | Phase II Axitinib (AG-013736) in Elderly Glioblastoma Multiforme (GBM) Patients | Phase 2 | terminated | Jan 11, 2012 | University of Cincinnati | transferred study sponsor | Other (stated, no rule matched) |
| NCT01526837 | Bevacizumab (Avastin) Into the Tumor Resection Cavity in Subjects With Glioblastoma… | Phase 1 | terminated | Feb 6, 2012 | Brain & Spine Surgeons of New York | Investigators decision | Other (stated, no rule matched) |
| NCT01413438 | Bevacizumab With or Without Surgery for Adult Glioblastomas | Phase 2 | withdrawn | Aug 10, 2011 | National Institute of Neurological Disorders and Stroke (NINDS) | not stated | Not stated |
| NCT00112866 | Cilengitide in Treating Patients Who Are Undergoing Surgery for Recurrent or Progressive… | Phase 2 | terminated | Jun 3, 2005 | National Cancer Institute (NCI) | due to poor accrual | Enrollment / accrual |
| NCT02039778 | Stem Cell Radiotherapy and Temozolomide for Newly Diagnosed High-grade Glioma(STRONG) | N/A | terminated | Jan 20, 2014 | Beth Israel Medical Center | Poor Accural | Other (stated, no rule matched) |
| NCT01310855 | Cediranib Maleate With or Without Gefitinib in Treating Patients With Recurrent or… | Phase 2 | terminated | Mar 9, 2011 | University College, London | closed to recruitment early due to AstraZeneca not developing cediranib further | Enrollment / accrual |
| NCT02648633 | Stereotactic Radiosurgery With Nivolumab and Valproate in Patients With Recurrent… | Phase 1 | terminated | Jan 7, 2016 | University of Virginia | The pharmaceutical company (BMS) would no longer provide nivolumab for the study, so the study was… | Sponsor / business decision |
| NCT02129335 | Stress, Exercise Behavior and Survival in Patients With Newly Diagnosed Glioblastoma and…(TOGETHER) | — | terminated | May 2, 2014 | University Hospital, Basel, Switzerland | insufficient enrollment | Enrollment / accrual |
| NCT01122901 | Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With… | Phase 2 | terminated | May 13, 2010 | National Cancer Institute (NCI) | Stopped prematurely by Company due to decision to terminate all CTEP supplied drug for further… | Sponsor / business decision |
| NCT02194452 | Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young… | N/A | withdrawn | Jul 18, 2014 | Sue O'Dorisio | not stated | Not stated |
| NCT01996527 | 3T MRI Biomarkers of Glioma Treatment Response | Early Phase 1 | terminated | Nov 27, 2013 | Vanderbilt-Ingram Cancer Center | PI left institution | Investigator |
| NCT02967380 | Gadobutrol Versus Gadopentetate Dimeglumine or Gadobenate Dimeglumine Before DCE-MRI in… | N/A | terminated | Nov 18, 2016 | University of Southern California | Insufficient Accrual | Enrollment / accrual |
| NCT02175745 | 18F-FDOPA PET/CT or PET/MRI in Measuring Tumors in Patients With Newly-Diagnosed or… | N/A | terminated | Jun 26, 2014 | Erik Mittra | Re-evaluate indication with the referring physicians | Other (stated, no rule matched) |
| NCT01902771 | Dendritic Cell Vaccine Therapy With In Situ Maturation in Pediatric Brain Tumors | Phase 1 | terminated | Jul 18, 2013 | Edward Ziga | Lack of Accrual | Enrollment / accrual |
| NCT00456612 | Radiosurgery for Glioblastoma Multiforme | Phase 1 / Phase 2 | terminated | Apr 5, 2007 | Beth Israel Deaconess Medical Center | Poor accrual | Enrollment / accrual |
| NCT00171938 | Open-label Trial of Imatinib Mesylate in Patients With Unresectable Recurrent… | Phase 2 | terminated | Sep 15, 2005 | Novartis | not stated | Not stated |
| NCT02876003 | Efficacy and Safety of G-202 in PSMA-Positive Glioblastoma | Phase 2 | withdrawn | Aug 23, 2016 | GenSpera, Inc. | This study has been withdrawn prior to enrollment. | Enrollment / accrual |
| NCT01148966 | Aminolevulinic Acid During Surgery in Treating Patients With Malignant Brain Tumors | Phase 1 | terminated | Jun 23, 2010 | University of Washington | not stated | Not stated |
| NCT02025231 | Image Guided Reirradiation of High-grade Glioma | Phase 1 / Phase 2 | terminated | Dec 31, 2013 | Rigshospitalet, Denmark | Slow accrual | Enrollment / accrual |
| NCT02394665 | Dose Escalated MRSI Guided Radiation Therapy in Glioblastoma | Phase 2 | terminated | Mar 20, 2015 | University of Miami | Lack of Accrual/Enrollment | Enrollment / accrual |
| NCT02841332 | Multimodal Imaging Analysis During Treatment With Bevacizumab in Patients With Recurrent…(IMAGLIO) | N/A | terminated | Jul 22, 2016 | University Hospital, Toulouse | lack of recruitment | Enrollment / accrual |
| NCT00473408 | The Effect of Radiotherapy and Temozolomide on the Tumor Vasculature and Stem Cells in…(Gliomstudien) | — | terminated | May 15, 2007 | Haukeland University Hospital | Moved to another country, not possible to recruit from abroad. | Enrollment / accrual |
| NCT02371031 | FDOPA-PET/MRI for the Pre-operative Evaluation of Gliomas | Phase 1 | terminated | Feb 25, 2015 | Washington University School of Medicine | Funding source for study ended. | Funding |
| NCT00574964 | Gliadel Wafers and Temodar in the Treatment of Glioblastoma Multiforme(Temodar) | Phase 2 | terminated | Dec 17, 2007 | University of Iowa | PI left the institution. | Investigator |
| NCT01989052 | Ph 1/2 CTO With Lomustine for Bevacizumab-Naive Recurrent Glioma | Phase 1 | terminated | Nov 20, 2013 | Annick Desjardins | This study was terminated early due to funding issues prior to completion of phase I | Funding |
| NCT02060955 | Randomized Phase 2 Study to Investigate Efficacy of ALECSAT in Patients With GBM Measured… | Phase 2 | terminated | Feb 12, 2014 | CytoVac A/S | Substantial design modifications required. | Other (stated, no rule matched) |
| NCT02031965 | Oncolytic HSV-1716 in Treating Younger Patients With Refractory or Recurrent High Grade… | Phase 1 | terminated | Jan 9, 2014 | Pediatric Brain Tumor Consortium | not stated | Not stated |
| NCT01445691 | More Complete Removal of Malignant Brain Tumors by Fluorescence-Guided Surgery | Phase 2 | withdrawn | Oct 4, 2011 | Constantinos Hadjipanayis | not stated | Not stated |
| NCT01499251 | Clinical Study on the Safety and Tolerability of Macitentan in Combination With… | Phase 1 | terminated | Dec 26, 2011 | Actelion | Results did not clearly support continuing development in recurrent GBM | Other (stated, no rule matched) |
| NCT01351519 | A Study of Aminolevulinic Acid Used to Enhance Visualization and Surgical Removal of… | Phase 2 | terminated | May 11, 2011 | MultiCare Health System Research Institute | Limited staff available for enrollment and limited availability of drug | Enrollment / accrual |
| NCT01830101 | A Phase III Study of Re-Irradiation in Recurrent Glioblastoma | Phase 3 | withdrawn | Apr 12, 2013 | AHS Cancer Control Alberta | This study will not be proceeding due to lack of funding from anticipated sources | Funding |
| NCT01249105 | MK-2206 for Recurrent Malignant Glioma | Phase 2 | withdrawn | Nov 29, 2010 | Dana-Farber Cancer Institute | Merck (supplier of study drug \& funding) has undergone a large reprioritization, in which they had… | Funding |
| NCT01756729 | Post-approval Study of NovoTTF-100A in Recurrent GBM Patients | Phase 4 | terminated | Dec 27, 2012 | NovoCure Ltd. | Amendment of Study Protocol | Other (stated, no rule matched) |
| NCT00703859 | Combining Radiotherapy and Temozolomide With Dichloroacetate in Patients With Newly… | Phase 1 | withdrawn | Jun 24, 2008 | AHS Cancer Control Alberta | not stated | Not stated |
| NCT01954030 | Phase 1/2 CTO + Bevacizumab for Recurrent Glioma Post-Bevacizumab Failure | Phase 1 | terminated | Oct 1, 2013 | Annick Desjardins | Study terminated early due to funding reasons prior to completing Phase 1 | Funding |
| NCT02521090 | EGFRBi-Armed Autologous T Cells in Treating Patients With Recurrent or Refractory… | Phase 1 / Phase 2 | withdrawn | Aug 13, 2015 | Barbara Ann Karmanos Cancer Institute | Due to lack of funding and a primary co-investigator of the trial leaving the institution. | Investigator |
| NCT01189240 | RO4929097and Bevacizumab in Treating Patients With Progressive or Recurrent Malignant… | Phase 1 / Phase 2 | terminated | Aug 26, 2010 | National Cancer Institute (NCI) | Company decided to stop development of drug - 7/31/12 | Sponsor / business decision |
| NCT01260467 | Memantine for Recurrent Glioblastoma | Phase 2 | terminated | Dec 15, 2010 | University of Rochester | not stated | Not stated |
| NCT02599090 | Phase II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or… | Phase 2 | withdrawn | Nov 6, 2015 | M.D. Anderson Cancer Center | Multi phase study did not progress to Phase II. Phase I registered as NCT00734526. | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Mar 22, 2018source: clinicaltrials